



Press release 22 May 2026

**Diamyd Medical announces that Niklas Axelsson has decided to leave his position as CFO to take on a new role in another company**

A review to find a successor will now begin, and Niklas will remain with the company for some time to enable a handover to this person.

"Although Niklas has worked for Diamyd for a relatively short period, he has left a mark on the organization. I want to express gratitude on behalf of the company – especially regarding the role he played in our most recent fund raising – and wish him success in his continued career," says Anders Essen-Möller, CEO of Diamyd Medical.

**About Diamyd Medical**

Diamyd Medical is a Swedish biotechnology company focused on precision medicine approaches for type 1 diabetes and biological manufacturing. The company's investigational drug candidate retogatein, based on recombinant GAD65, was evaluated in the Phase 3 DIAGNODE-3 trial in recent-onset type 1 diabetes. The Company has established a facility for manufacturing of biological products in Umeå, Sweden. Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.

**For further information, please contact:**

Anders Essen-Möller, CEO

Phone: +46 705 51 06 79

E-mail: [anders.essen-moller@diamyd.com](mailto:anders.essen-moller@diamyd.com)

**Diamyd Medical AB (publ)**

Box 7349, SE-103 90 Stockholm, Sweden. Phone: +46 8 661 00 26

E-mail: [info@diamyd.com](mailto:info@diamyd.com) Org. nr: 556242-3797 Website: <https://www.diamyd.com>

The information was provided by the contact person above, for publication on 08.30 CET, May 22, 2026.